Property brokerage Compass on Wednesday dropped its lawsuit against Zillow, ending a legal clash over how home listings can be marketed online. For the past few years, Compass — now the largest real ...

The industry’s largest brokerage had sued the home search site over its Listings Access Standards, which conflict with Compass’ marketing approach. Compass' signature 3-phased marketing strategy, in ...

The hidden nature of composite damage poses an unusual challenge for the cycling industry. “A CFRP frame can sustain significant internal damage in the form of delamination, matrix cracking or ply ...

Can’t decide between Jeep’s two smallest SUVs? This comparison should clear up any confusion. The current Jeep Cherokee is the sixth generation of the SUV, having been introduced last year. It’s based ...

The reaction to MongoDB’s mixed earnings report shows that it’s a tough world out there for software companies. While the database-software company delivered with its latest results Monday, it came up ...

MongoDB's valuation is falling fast after the company's latest quarterly report. The software specialist reported Q4 sales and earnings that beat expectations, but forward guidance was softer than ...

MongoDB (MDB) shares crashed and fell more than 20% in extended trading on Monday after the enterprise software company reported mixed guidance compared to Wall Street's forecast. Looking to the first ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/mongodb-inc-announces-fourth-quarter-fiscal-2026-financial-results-302701531 ...

IDAHO FALLS, Idaho (KIFI) – In an era of fiscal reckoning, District 91's Career and Technical Education Center (CTEC) may be moving to a new home. CTEC and Compass Academy “The board asked us to ...

MongoDB (MDB) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended January 2026. This widely-known consensus outlook gives a ...

Compass Pathways has announced that its investigational psilocybin treatment has successfully met its primary endpoint in a second Phase 3 clinical trial moving it one step closer to FDA submission.